Provided by Tiger Trade Technology Pte. Ltd.

LUYE PHARMA

1.830
-0.035-1.88%
Volume:29.03M
Turnover:52.75M
Market Cap:7.31B
PE:9.86
High:1.860
Open:1.860
Low:1.800
Close:1.865
52wk High:3.830
52wk Low:1.730
Shares:4.00B
HK Float Shares:4.00B
Volume Ratio:1.36
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.186
ROE:4.27%
ROA:2.18%
PB:0.40
PE(LYR):9.86
PS:1.02

Loading ...

Shandong Boan Biotech Confirms RMB 75 Million Finance Lease Asset Sale Price in Supplemental Pact

Reuters
·
Yesterday

Shandong Boan Biotech Files HKEX Next-Day Disclosure Return on Share Buyback Cancellation

Reuters
·
Yesterday

METIS TECHBIO-P Jumps 7% After Strategic Pact and Stock Connect Inclusion

Stock News
·
Sep 08

Shandong Boan Biotech Files HKEX Next-Day Disclosure Return on Share Repurchase for Cancellation

Reuters
·
Sep 07

Shandong Boan Biotech Files HKEX Next-Day Return Disclosing Share Buyback

Reuters
·
Sep 04

多部委联合发布房地产新政,美联储主席鹰派信号引发市场关注

Stock News
·
Aug 31

Luye Pharma H1 2026: Revenue Drops 5.6 % to RMB 3.00 B, Net Profit Climbs 6.5 % on Lower Costs; CNS Therapies Lead Growth

Bulletin Express
·
Aug 30

Shandong Boan Biotech Files HKEX Next-Day Return Disclosing Share Buyback at HKD 3.74 Each

Reuters
·
Aug 28

LUYE PHARMA: UBS Group AG Disposes of Shares, Long Position Falls to 12.98%

HK Disclosure
·
Aug 28

Shandong Boan Biotech Enters RMB 75 Million Sale-and-Leaseback Deal with Industrial Bank Financial Leasing

Reuters
·
Aug 27

Luye Pharma's Vaccine for Cervical Precancerous Lesions to Enter Phase II Trial

MT Newswires Live
·
Aug 21

Luye Pharma Sets 29 Aug 2026 Board Meeting to Approve 1H 2026 Results and Review Interim Dividend

Bulletin Express
·
Aug 17

Luye Pharma Schedules Board Meeting to Review Interim Results, Weigh Dividend

Reuters
·
Aug 17

Shandong Boan Biotech Completes China Phase Ia Trial of Ba1302 CD228-Targeted ADC

Reuters
·
Aug 14

Shandong Boan Biotech Schedules Board Meeting on Interim Results, Dividend Review

Reuters
·
Aug 14

Luye Pharma Completes US Bridging Trial for Neurological Drug Candidate

MT Newswires Live
·
Aug 06

Luye Pharma completes U.S. bridging trial for VMAT2/Sigma-1R dual-acting drug LY03015

Bulletin Express
·
Aug 05

Shandong Boan Files Brazil Marketing Application for Ba9101 Aflibercept Biosimilar with Anvisa

Reuters
·
Aug 05

Movement Alert|Luye Pharma Declines 5.41% in Regular Trading, Trading at HK$2.09

Market Focus
·
Jul 17

Movement Alert|Luye Pharma Rises 6.45% in Regular Trading, Convertible Bond Redemption and Positive Clinical Data Drive Three-Day Rally

Market Focus
·
Jul 15